HSA-based multi-target combination therapy: regulating drugs’ release from HSA and overcoming single drug resistance in a breast cancer model
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HSA-based multi-target combination therapy: regulating drugs’ release from HSA and overcoming single drug resistance in a breast cancer model
Authors
Keywords
-
Journal
DRUG DELIVERY
Volume 25, Issue 1, Pages 321-329
Publisher
Informa UK Limited
Online
2018-01-19
DOI
10.1080/10717544.2018.1428245
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Doughnut-shaped bovine serum albumin nanoparticles loaded with doxorubicin for overcoming multidrug-resistant in cancer cells
- (2018) Zahra Kayani et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Recent Advances in the Application of Vitamin E TPGS for Drug Delivery
- (2018) Conglian Yang et al. Theranostics
- Overcoming photodynamic resistance and tumor targeting dual-therapy mediated by indocyanine green conjugated gold nanospheres
- (2017) Wei Li et al. JOURNAL OF CONTROLLED RELEASE
- Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier
- (2017) Yi Gou et al. MOLECULAR PHARMACEUTICS
- Sequential Delivery of Cyclopeptide RA-V and Doxorubicin for Combination Therapy on Resistant Tumor and In Situ Monitoring of Cytochrome c Release
- (2017) Huachao Chen et al. Theranostics
- TheXChemExplorergraphical workflow tool for routine or large-scale protein–ligand structure determination
- (2017) Tobias Krojer et al. Acta Crystallographica Section D-Structural Biology
- Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance
- (2016) Nicole Seebacher et al. FREE RADICAL BIOLOGY AND MEDICINE
- A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery
- (2016) Yuling Bao et al. JOURNAL OF CONTROLLED RELEASE
- Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain
- (2016) Jinxu Qi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics
- (2016) Kyung Chan Park et al. Metallomics
- Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents
- (2016) Jinxu Qi et al. MOLECULAR PHARMACEUTICS
- Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain
- (2016) Jinxu Qi et al. MOLECULAR PHARMACEUTICS
- Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer
- (2016) Yi Gou et al. Oncotarget
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cisplatin binding to human serum albumin: a structural study
- (2015) Giarita Ferraro et al. CHEMICAL COMMUNICATIONS
- Linking the future of anticancer metal-complexes to the therapy of tumour metastases
- (2015) Alberta Bergamo et al. CHEMICAL SOCIETY REVIEWS
- Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
- (2015) Yi Gou et al. CURRENT PHARMACEUTICAL DESIGN
- Editorial (Thematic Issue: HSA-Based Drug Development and Drug Delivery Systems)
- (2015) Feng Yang et al. CURRENT PHARMACEUTICAL DESIGN
- Designing Prodrugs Based on Special Residues of Human Serum Albumin
- (2015) Yi Gou et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain
- (2015) Yi Gou et al. MOLECULAR PHARMACEUTICS
- Kinetics and mechanistic investigation into the possible activation of imidazolium trans-[tetrachloridodimethylsulfoxideimidazoleruthenate(iii)], NAMI-A, by 2-mercaptoethane sulfonate
- (2014) Risikat Ajibola Adigun et al. DALTON TRANSACTIONS
- Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin
- (2014) Yao Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer
- (2014) Alberta Bergamo et al. INVESTIGATIONAL NEW DRUGS
- A clinical update of using albumin as a drug vehicle — A commentary
- (2014) Felix Kratz JOURNAL OF CONTROLLED RELEASE
- Combination of Small Molecule Prodrug and Nanodrug Delivery: Amphiphilic Drug–Drug Conjugate for Cancer Therapy
- (2014) Ping Huang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Coencapsulated Doxorubicin and Bromotetrandrine Lipid Nanoemulsions in Reversing Multidrug Resistance in Breast Cancer in Vitro and in Vivo
- (2014) Xi Cao et al. MOLECULAR PHARMACEUTICS
- Nanoparticles for Combination Drug Therapy
- (2013) Liang Ma et al. ACS Nano
- A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery
- (2013) Changli Du et al. BIOMATERIALS
- Advances in Copper Complexes as Anticancer Agents
- (2013) Carlo Santini et al. CHEMICAL REVIEWS
- Increasing the Bioavailability of RuIIIAnticancer Complexes through Hydrophobic Albumin Interactions
- (2013) Michael I. Webb et al. CHEMISTRY-A EUROPEAN JOURNAL
- Polymeric Micelles for Multidrug Delivery and Combination Therapy
- (2013) Moom Sinn Aw et al. CHEMISTRY-A EUROPEAN JOURNAL
- Human serum albumin-based design of a diflunisal prodrug
- (2013) Feng Yang et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Novel Mixed-Ligand Copper(I) Complexes: Role of Diimine Ligands on Cytotoxicity and Genotoxicity
- (2013) Valentina Gandin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Subdomain IB Is the Third Major Drug Binding Region of Human Serum Albumin: Toward the Three-Sites Model
- (2013) Ferenc Zsila MOLECULAR PHARMACEUTICS
- Engineering Particles for Therapeutic Delivery: Prospects and Challenges
- (2012) Yan Yan et al. ACS Nano
- Gene and doxorubicin co-delivery system for targeting therapy of glioma
- (2012) Shuhuan Liu et al. BIOMATERIALS
- Graphene oxide based multilayer capsules with unique permeability properties: facile encapsulation of multiple drugs
- (2012) Rajendra Kurapati et al. CHEMICAL COMMUNICATIONS
- Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy
- (2012) Priyambada Parhi et al. DRUG DISCOVERY TODAY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules
- (2011) Muhammad Hanif et al. CHEMICAL COMMUNICATIONS
- Human serum albumin–thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury
- (2011) Masato Furukawa et al. JOURNAL OF CONTROLLED RELEASE
- Clinical impact of serum proteins on drug delivery
- (2011) Felix Kratz et al. JOURNAL OF CONTROLLED RELEASE
- Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies
- (2011) Tore-Geir Iversen et al. Nano Today
- PHENIX: a comprehensive Python-based system for macromolecular structure solution
- (2010) Paul D. Adams et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Tumor delivery of macromolecular drugs based on the EPR effect
- (2010) Vladimir Torchilin ADVANCED DRUG DELIVERY REVIEWS
- Copper Compounds in Cancer Chemotherapy
- (2010) L. Ruiz-Azuara et al. CURRENT MEDICINAL CHEMISTRY
- Combination therapy: Opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines
- (2009) Francesca Greco et al. ADVANCED DRUG DELIVERY REVIEWS
- Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells
- (2008) Dirk Garmann et al. JOURNAL OF CONTROLLED RELEASE
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
- (2008) Felix Kratz JOURNAL OF CONTROLLED RELEASE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search